60 Degrees Pharmaceuticals, Inc.
SXTPNASDAQHealthcareBiotechnology
Regular session
$1.09
−$0.04 · -3.54%
SXTP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
49
Fair Value
Momentum
27
Weakening
Sentiment
55
Mixed
Risk resilience
15
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company website60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Geoffrey Stuart Dow
- Listed since
- Jul 12, 2023
- Employees
- 3
Market position
Day range
Current $1.09
52-week range
Current $1.09
- Open
- $1.13
- Previous close
- $1.13
- Volume
- 20.97K
- 0.18× average
- Average volume
- 114.16K
- Average daily volume
- Market cap
- 879.14K USD
- Beta
- 2.54
- Market reference 1
- 50-day average
- $1.4307
- -23.81% below average
- 200-day average
- $2.3868
- -54.33% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.24K USD
- P/E (TTM)
- -0.18×
- P/B (TTM)
- 1.11×
- P/S (TTM)
- 0.79×
- EV / EBITDA
- -0×
- Earnings yield
- -541.58%
- Free cash flow yield
- -519.44%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 19.42%
- Operating margin
- -774.90%
- Net margin
- -730.23%
- Return on equity
- -212.76%
- Return on assets
- -137.31%
- Return on invested capital
- -219.65%
Financial health
- Debt / equity
- 0.06×
- Current ratio
- 2.66×
- Altman Z-score
- -22.16
- Piotroski F-score
- 2 of 9
Earnings
- EPS beat rate
- 18%
- 2 beats, 9 misses, 0 met estimates
- Average EPS surprise
- -20.55%
- 11 comparable reports
- Latest EPS result
- -0.9
- Estimate -0.74 · Miss by 21.62%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 20, 2026 | 1:4 | — | — |
Stock split | Feb 24, 2025 | 1:5 | — | — |
Stock split | Aug 12, 2024 | 1:12 | — | — |
Effective Jan 20, 2026
1:4
Effective Feb 24, 2025
1:5
Effective Aug 12, 2024
1:12
SXTP peers
Continue in GoAI
Research SXTPresearch.disclaimer